Draft:Creative Biolabs

Creative Biolabs
Company type
Corporation
IndustryBiotechnology
HeadquartersShirley, New York 11967, US
Websitewww.creative-biolabs.com/aboutus.html
https://www.creativebiolabs.net/

Creative Biolabs is a biotechnology and pharmaceutical contract research organization (CRO) headquartered in Shirley, New York, United States..[1] The company offers customized solutions for drug discovery and development, encompassing antibody discovery and engineering, biomanufacturing, and a range of in vitro and in vivo assays.[2]

History

In June 2016, Creative Biolabs launched its first scholarship program, marking its commitment to corporate social responsibility.[3] In July 2021, the company signed a Letter of Intent with Enzolytics, Inc. for the joint production and commercialization of anti-HTLV-1 monoclonal antibodies.[4] In 2025, in response to the call from People for the Ethical Treatment of Animals (PETA UK), Creative Biolabs joined a growing list of leading institutions—including the University of Bath, University of Bristol, and King's College London—that have publicly stated they neither conduct nor intend to conduct forced swim tests on animals.[5]

Corporate Responsibility and Education Support

The Creative Biolabs Scholarship Program, established in June 2016, provides annual financial awards to outstanding undergraduate and post-graduate students worldwide who major in life sciences, biochemistry, biopharmaceutical science, or molecular biology.[3] The program aims to encourage and support the growth of the next generation of scientific researchers. For example, Ashley Harkins, a PhD student in neuroscience at UMass Chan Medical School, was named the 2022 Creative Biolabs Scholarship recipient.[6]

In addition to the scholarship, the company has sponsored and supported educational and community initiatives such as science conferences, research symposia, and student competitions in the life sciences, including serving as a corporate sponsor of the European Zebrafish Society in 2025.

Academic Engagement

Creative Biolabs supports the dissemination of scientific knowledge and academic exchange by organizing regular professional webinars[7] to support biotechnology education and industry collaboration. These webinars feature experts from U.S. universities and research institutes, covering frontier topics in antibody engineering, cell therapy, neuroscience and gene therapy.

Events successfully held from 2024 include:

  • Generation of a Dual-Function Multi-Engager Antibody for Simultaneous Targeting of NK Cells and Tumor Cells (22 May 2025)–Bruce Walcheck, University of Minnesota, described a strategy for developing multifunctional antibodies that engage both NK cells and tumor cells.[10]
  • Neural Circuits of Survival: How the Brain Orchestrates Defensive Behavior (June 25, 2025) – Jonathan P. Fadok, Tulane University, discussed newly identified cortico-amygdala circuits regulating freezing and flight responses.[11]

Research and Development

The company's research and development spans multiple therapeutic areas, including antibody therapy, cell therapy, and gene therapy.[16]

In antibody therapy, its activities include recombinant and bispecific antibodies[17] (BsAbs), single-domain antibodies (sdAbs), antibody-drug conjugates (ADCs)[18], bioconjugation and linker chemistry, de novo antibody discovery, and antibody discovery with premade libraries[19]. Several of these tools and services have been referenced in peer-reviewed studies, including foralumab and teplizumab[20], as well as hybridoma characterization by amplification and sequencing, and Fab antibody production[21]

For cell therapy, the company engages in CAR-T/NK cell therapy development and stem cell therapy platforms.[22] Experimental models such as primary mouse cortical neuron cultures combined with MEA analysis[23] and 3D cell culture chips[24] have been used in published studies.

In addition, the company offers in vitro toxicology testing, supporting drug safety assessment through cellular and molecular assays, which continues to grow due to increased emphasis on preclinical screening and non-animal testing alternatives.[25]

Within gene therapy, its activities include oncolytic virus development, mRNA discovery[26] and optimization, viral vector engineering, and formulation and delivery optimization. Certain viral vectors[27] and antibodies used in these studies were obtained from the company.

References

  1. ^ "Creative Biolabs". National Center for Biotechnology Information. National Institutes of Health. Retrieved 18 November 2025.
  2. ^ "Creative Biolabs Inc". bloomberg.com. Bloomberg. Retrieved 18 November 2025.
  3. ^ a b "Creative Biolabs Scholarship Program". The Company of Biologists. The Company of Biologists. Archived from the original on 27 October 2016. Retrieved 2016-10-27.
  4. ^ "Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies". Nasdaq. Nasdaq. 20 July 2021. Retrieved 18 November 2025.
  5. ^ Margarita, Sachkova (2 May 2025). "Good News for Mice and Rats! Creative Biolabs Drops Cruel Forced Swim Test". PETA UK. People for the Ethical Treatment of Animals. Retrieved 25 August 2025.
  6. ^ Hallie, Leo; Kaylee, Pugliese (9 January 2023). "PhD student aims to develop novel immunotherapies to conquer ALS". UMass Chan Medical School. UMass Chan Medical School. Retrieved 18 November 2025.
  7. ^ "CAR-T Cell Targeted Delivery of Secreted Therapeutics for Solid Tumors". onenucleus.com. One Nucleus. Retrieved 18 November 2025.
  8. ^ "Webinar: EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development". medical-xprt.com. Medical XPRT – The Medical Industry Online. Retrieved 18 November 2025.
  9. ^ "Webinar: Programmable Molecular Tools for Biology and Genome Editing". onenucleus.com. One Nucleus. Retrieved 18 November 2025.
  10. ^ Bella, Smith (2 May 2025). "Education: Webinar on generation of a dual-function multi-engager antibody for simultaneous targeting NK cells and tumor cells". bioinformatics.org. Bioinformatics. Retrieved 18 November 2025.
  11. ^ "Coming Webinar: Neural Circuits of Survival: How the Brain Orchestrates Defensive Behavior". onenucleus.com. One Nucleus. Retrieved 18 November 2025.
  12. ^ "Open Webinar: The Double-Edged Role of Extracellular Vesicles in Alzheimer's Disease". rsc.org. Royal Society of Chemistry. Retrieved 18 November 2025.
  13. ^ "Tumoroid-on-a-Chip as a physiologically relevant model for immunotherapy". bioindustry.org. BioIndustry Association. Retrieved 18 November 2025.
  14. ^ "Neurodegenerative Functions of Microglia in Alzheimer's Disease". industryevents.com. Industry Events. Retrieved 18 November 2025.
  15. ^ "CAR-T Cell Targeted Delivery of Secreted Therapeutics for Solid Tumors". lifesciencesweek.london. London Life Sciences Week. Retrieved 18 November 2025.
  16. ^ "Creative Biolabs". selectscience.net. Select Science. Retrieved 18 November 2025.
  17. ^ "Recombinant Anti-Helicobacter Pylori Antibody Market Insights". verifiedmarketreports.com. Verified Market Reports. Retrieved 18 May 2025.
  18. ^ "Immunotoxins Market (2025 - 2030)". grandviewresearch.com. Grand View Research. Retrieved 18 November 2025.
  19. ^ Craig, Bradley (29 September 2025). "Creative Biolabs Enhances Antibody Discovery with Premade Libraries". labmanager.com. Lab Manager. Retrieved 30 September 2025.
  20. ^ Tran Quang, Christine C. T.; Zaniboni, Benedetta; Humeau, Romain; Lengliné, Etienne; Dourthe, Marie‑Émilie; Ganesan, Rajkumar; Singh, Sanjaya; Scheer, Justin M.; Asnafi, Vahid; Ghysdael, Jacques (10 September 2020). "Preclinical efficacy of humanized, non‑FcγR‑binding anti‑CD3 antibodies in T‑cell acute lymphoblastic leukemia". *Blood*. 136 (11): 1298–1302. doi:10.1182/blood.2019003801. PMID 32483610.
  21. ^ Wanczyk, Heather; Barker, Tolga; Rood, Debra; Zapata, Daniel I; Howell, Amy R; Richardson, Stewart K; Zinckgraf, John; Marusov, Gregory P; Lynes, Michael A; Silbart, Lawrence K (2013). "Cloning and Characterization of a Hybridoma Secreting a 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Specific Monoclonal Antibody and Recombinant F(ab)". Toxins. 5 (3): 568–589. doi:10.3390/toxins5030568. PMC 3705279. PMID 23518474.
  22. ^ "Cell Cryopreservation Market, by Type (Cryopreservation media, Equipment), by Application (Stem cells, Oocytes cells, Sperm cells, Others), by End User (Pharmaceutical and biotechnology company, Research institute, Others): Global Opportunity Analysis and Industry Forecast, 2022 - 2032". alliedmarketresearch.com. Allied Market Research. Retrieved 18 November 2025.
  23. ^ Rohn, Troy T; Radin, Dean; Brandmeyer, Tracy; Linder, Barry J; Andriambeloson, Emile; Wagner, Stéphanie; Kehler, James; Vasileva, Ana; Wang, Huaien; Mee, John L; Fallon, James H (2023-06-20). "Genetic modulation of the HTR2A gene reduces anxiety-related behavior in mice". PNAS Nexus. 2 (6): pgad170. doi:10.1093/pnasnexus/pgad170. PMC 10281383. PMID 37346271.{{cite journal}}: CS1 maint: article number as page number (link)
  24. ^ Tevlek, Atakan; Kecili, Seren; Ozcelik, Ozge S; Kulah, Haluk; Tekin, H Cumhur (2023-01-18). "Spheroid Engineering in Microfluidic Devices". ACS Omega. 8 (4): 3630–3649. doi:10.1021/acsomega.2c06052. PMC 9893254. PMID 36743071.
  25. ^ "In Vitro Toxicology Testing Market by Product & Service (Assays (ELISA & Western Blot), Equipment, Consumable, Software), Toxicity Endpoints (ADME, Genotoxicity, Cytotoxicity), Technology, Method, Industry (Pharma, Cosmetics) - Global Forecast to 2028". researchandmarkets.com. Research and Markets. October 2025. Retrieved 18 November 2025.
  26. ^ "CircRNA Synthesis Market (2025 - 2030)". grandviewresearch.com. Grand View Research. Retrieved 18 November 2025.
  27. ^ Foskolou, Iosifina P; Barbieri, Laura; Vernet, Aude; Bargiela, David; Cunha, Pedro P; Velica, Pedro; Suh, Eunyeong; Pietsch, Sandra; Matuleviciute, Rugile; Rundqvist, Helene; McIntyre, Dominick; Smith, Ken G C; Johnson, Randall S (2020-09-22). "The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome". Blood Advances. 4 (18): 4483–4493. doi:10.1182/bloodadvances.2020002309. PMC 7509862. PMID 32941648.

https://www.youtube.com/watch?v=SvZPTK-5IBM

https://www.youtube.com/watch?v=PhPAjdffc6c

https://www.youtube.com/watch?v=mdJtenlL72Y

https://www.youtube.com/watch?v=VXJVCJbmJKE

https://www.youtube.com/watch?v=2fLvjlyjdZs

https://www.youtube.com/watch?v=s6jDFc5pd5I

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.